



## Kura Oncology to Participate in Jefferies Global Healthcare Conference

May 29, 2024

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Jefferies Global Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 3:00 p.m. ET / 12:00 p.m. PT on June 5, 2024. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at [www.kuraoncology.com](http://www.kuraoncology.com), with an archived replay following the event.

### About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in NPM1-mutant R/R AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in NPM1-mutant and KMT2A-rearranged newly diagnosed and R/R AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent HNSCC (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura's website at <https://kuraoncology.com/> and follow us on [X](#) and [LinkedIn](#).

### Contacts

#### Investors:

Pete De Spain  
Executive Vice President, Investor Relations &  
Corporate Communications  
(858) 500-8833  
[pete@kuraoncology.com](mailto:pete@kuraoncology.com)

#### Media:

Alexandra Weingarten  
Associate Director, Corporate Communications &  
Investor Relations  
(858) 500-8822  
[alexandra@kuraoncology.com](mailto:alexandra@kuraoncology.com)



Source: Kura Oncology, Inc.